Organogenesis Holdings Inc.

NasdaqCM:ORGO Rapport sur les actions

Capitalisation boursière : US$231.6m

Organogenesis Holdings Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Organogenesis Holdings ont diminué à un taux annuel moyen de -73.1%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 34.1% par an. Les revenus ont augmenté de en à un taux moyen de 1.7% par an.

Informations clés

-73.10%

Taux de croissance des bénéfices

-73.54%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.04%
Taux de croissance des recettes1.71%
Rendement des fonds propres-29.21%
Marge nette-22.23%
Dernière mise à jour des bénéfices30 Jun 2026

Mises à jour récentes des performances passées

Recent updates

Mise à jour du récit • Aug 09

ORGO: Reimbursement Pressures And Knee OA BLA Will Shape Balanced Future Prospects

Analysts have lowered their price target on Organogenesis Holdings stock from $3 to $2, citing updated expectations that take into account ongoing reimbursement-driven pressures on revenue and margins, as well as a lower assumed future P/E multiple. Analyst Commentary Recent research on Organogenesis Holdings highlights a mix of potential opportunity and clear near term challenges.
Mise à jour du récit • Jun 23

ORGO: Reimbursement Reset And Knee OA BLA Will Support Future Upside

Analysts have kept their $3 price target on Organogenesis Holdings intact, citing the view that reimbursement changes and a potential shakeout among smaller competitors could eventually help the company, while recently lowered guidance and limited near term revenue upside restrain expectations. What's in the News Organogenesis Holdings issued earnings guidance for the first half, second half, and full year 2026, indicating total net revenue in a range of $270.0 million to $310.0 million compared with $564.2 million reported for full year 2025, based on company guidance.
Seeking Alpha • Jun 15

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

Summary Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges. Management anticipates a gradual turnaround through 2026, with a potential acceleration in Q4. ReNu, its knee injection with a novel MOA and blockbuster potential, is awaiting FDA approval of its pending BLA. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 01

ORGO: Reimbursement Shakeout And Knee Osteoarthritis BLA Will Drive Future Upside

Analysts reduced their price target on Organogenesis Holdings to $3, citing reimbursement-driven structural shifts that could eventually benefit the company as smaller competitors exit. They also pointed to limited near-term revenue upside after management lowered guidance to reflect a steeper expected decline in 2026.
Mise à jour du récit • Feb 19

ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook

Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).
Mise à jour du récit • Feb 05

ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook

Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).
Mise à jour du récit • Jan 21

ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook

Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).
Article d’analyse • Jan 17

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%

Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...
Article d’analyse • Jan 11

Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Mise à jour du récit • Jan 06

ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook

Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).
Mise à jour du récit • Dec 18

ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside

Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.
Mise à jour du récit • Dec 04

ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion

Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).
Article d’analyse • Nov 27

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry

Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...
Mise à jour du récit • Nov 20

ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion

Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.
Mise à jour du récit • Aug 15

CMS Reform And Capacity Expansion Will Unlock Long Term Value

With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.
Article d’analyse • May 04

Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
User avatar
Nouveau récit • Apr 25

LCD Delays And ReNu Progress Will Unlock Market Potential

Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.
Article d’analyse • Mar 02

There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise

The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...
Seeking Alpha • Oct 15

Organogenesis: Lurking Disruption With Recovery To Follow

Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking Alpha
Article d’analyse • Sep 09

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...
Article d’analyse • Jun 15

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...
Seeking Alpha • Jun 10

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking Alpha
Article d’analyse • May 21

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...

Ventilation des recettes et des dépenses

Comment Organogenesis Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqCM:ORGO Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 26457-10229957
31 Mar 26515-1531849
31 Dec 255642032645
30 Sep 25465-1329946
30 Jun 25430-1629243
31 Mar 25459-2029548
31 Dec 24482-129550
30 Sep 24455-728051
30 Jun 24448-1727251
31 Mar 24435626646
31 Dec 23433526644
30 Sep 234491328144
30 Jun 234571029143
31 Mar 234611329042
31 Dec 224511628240
30 Sep 224635927337
30 Jun 224607125936
31 Mar 224628325433
31 Dec 214679424931
30 Sep 214466223629
30 Jun 214336922624
31 Mar 213794320921
31 Dec 203381720320
30 Sep 20306-520317
30 Jun 20270-3720118
31 Mar 20266-4220317
31 Dec 19261-3920015
30 Sep 19250-4619214
30 Jun 19236-4818113
31 Mar 19215-5816811
31 Dec 18193-6515811
30 Sep 18183-6015010
30 Jun 18184-5214710
31 Mar 18187-3214210
31 Dec 17199-91349
31 Dec 16139-17936
31 Dec 1599-24744

Des revenus de qualité: ORGO n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: ORGO n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: ORGO n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 73.1% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de ORGO au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: ORGO n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 64.6% ).

Rendement des fonds propres

ROE élevé: ORGO a un retour sur capitaux propres négatif ( -29.21% ), car il n'est actuellement pas rentable.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/08/23 08:28
Cours de l'action en fin de journée2026/08/21 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Organogenesis Holdings Inc. est couverte par 8 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Michael GormanBTIG
Ross OsbornCantor Fitzgerald & Co.
Richard NewitterLeerink Partners LLC